Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Up 6.17%
As of Monday, November 09, Corvus Pharmaceuticals, Inc.’s CRVS share price has surged by 6.17%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Cynthia McLaughlin
Jenna Brashear
Michael Rose
| Share Statistics | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $815.7 | $203.5 | 45% |
|
| Shares Out (Mil) | 92.5 | 55.2 | 60% |
|
| Institutional Ownership | 95.5% | 93.3% | 67% |
|
| Float (Mil) | 73.0 | 40.4 | 54% |
|
| Beta | 1.52 | 1.05 | 83% |
|
| Avg Daily Volume (000s) | 899 | 569 | 68% |
|
| Price Change (52-week) |
8.7% | 38.8% | 62% |
|
| Growth | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (20.6%) | (10.7%) | 20% |
|
| EPS (5yr) | (21.3%) | 15.4% | 12 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.3%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.235) | ($0.803) | ($1.100) | |
| Month Ago EPS | ($0.228) | ($0.778) | ($1.068) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.228) | ($0.778) | ($1.068) | |
| Year/Year Chg | 6.8% | 50.9% | 103.9% | |
| Financials | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($64) | ($44) | 14% |
|
| EPS (TTM) | ($0.719) | ($1.400) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($35) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $-0 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $687 | $142 | 38% |
|
| Valuation | CRVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.91 | 1.96 | 77% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CRVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (42.3%) | (47.0%) | 13% |
|
| ROE | (45.9%) | (51.8%) | 16% |
|
| Liabilities to Assets | 6.9% | 29.6% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Corvus Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors